AMYGDALA vs CytoReason
AMYGDALA vs CytoReason, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: AMYGDALA is on 31/100 and CytoReason on 68/100.
Where each one leads
AMYGDALA
- agent readiness: 50/100 against 21/100
- headcount growth: +74.8% against +13.7%
CytoReason
- our overall score: 68/100 against 31/100
- domain rating: 40/100 against 1/100
- headcount: 116 against 9
- LinkedIn following: 12,830 against 9
At a glance
| Measure | AMYGDALA | CytoReason |
|---|---|---|
| What it is | Developing AI-driven technology for mental health treatments, focusing on PTSD. | Develops a computational model of the human body for drug discovery and development. |
| Category | Healthcare, PTSD, Mental Health, Personalized | Healthcare, Drug Discovery, Clinical Development, Biomarkers |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2017 | 2016 |
| Headquarters | Tel Aviv, Israel | Tel Aviv, Israel |
| Status | Inactive | Active |
Size, funding and growth
| Measure | AMYGDALA | CytoReason |
|---|---|---|
| Employees | 9 | 116 |
| Headcount growthLast 12 months | +74.8% | +13.7% |
| Total funding | Not published | $128M |
| Latest round | Not published | Series B |
| LinkedIn followers | 9 | 12,830 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | AMYGDALA | CytoReason |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 31/100 | 68/100 |
| Traction | 10/100 | 60/100 |
| Team | 60/100 | 70/100 |
| Search visibility | 15/100 | 30/100 |
| Quality | Not published | 78/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (50/100) | F (21/100) |
| Domain ratingLink authority, 0-100 | 1/100 | 40/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | AMYGDALA | CytoReason |
|---|---|---|
| Analytics | Not detected | Segment |
AMYGDALA vs CytoReason: common questions
Which is better, AMYGDALA or CytoReason?
On our 0-100 score CytoReason rates higher (68/100 against 31/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do AMYGDALA and CytoReason compare on the numbers?
AMYGDALA leads on agent readiness (50/100 against 21/100), headcount growth (+74.8% against +13.7%). CytoReason leads on our overall score (68/100 against 31/100), domain rating (40/100 against 1/100), headcount (116 against 9), LinkedIn following (12,830 against 9).
Read the full AMYGDALA review and pricing or the CytoReason review and pricing. You can also browse other AMYGDALA alternatives we track.